STSS - הכנסה תפעולית לפני ניכוי פחת sharpstechnology.com

Intense pricing competition with global suppliers is impacting dynamics, and at GURU.Markets, the absolute EBITDA level demonstrates this dependency, where 0.00 shapes the current metric. A revenue shortfall coupled with high R&D expenses is leading to the depletion of reserves. Meanwhile, Sharps Technology, Inc. (STSS) maintains pricing power thanks to its low dead-space syringes, which eliminate medication waste.

This indicator measures the net cash flow generated by the core business before accounting for asset depreciation, allowing for an assessment of real solvency and the internal efficiency of the operating model. An analysis of the operating result of Sharps Technology, Inc. (STSS) before depreciation and amortization demonstrates how successfully the company is scaling the production of self-destructing syringes and overcoming pressure from major competitors within current medical safety standards.